ezetimibe has been researched along with bms201038 in 9 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (bms201038) | Trials (bms201038) | Recent Studies (post-2010) (bms201038) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 128 | 13 | 106 |
| Protein | Taxonomy | ezetimibe (IC50) | bms201038 (IC50) |
|---|---|---|---|
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.0008 | |
| Microsomal triglyceride transfer protein large subunit | Homo sapiens (human) | 0.0056 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Bloedon, LT; McKenney, J; Rader, DJ; Samaha, FF; Sasiela, WJ | 1 |
| Davidson, MH | 1 |
| Ballantyne, CM; Catapano, AL; Norata, GD | 1 |
| Reiner, Z | 1 |
| Diekmann, J; Farr, M; Horstkotte, D; Mellwig, KP; van Buuren, F | 1 |
| Cai, T; Can, A; Castro, VM; Dligach, D; Du, R; Finan, S; Gainer, V; Murphy, S; Savova, G; Shadick, NA; Weiss, ST; Yu, S | 1 |
| Catapano, AL; Hovingh, GK; Raal, FJ | 1 |
| Hegele, RA; Tsimikas, S | 1 |
| Bacalbasa, N; Bratu, OG; Crismaru, I; Diaconu, CC; Gaman, MA; Pantea Stoian, A; Stanescu, AMA | 1 |
5 review(s) available for ezetimibe and bms201038
| Article | Year |
|---|---|
Novel nonstatin strategies to lower low-density lipoprotein cholesterol.
Topics: Animals; Anticholesteremic Agents; Azetidines; Benzimidazoles; Carrier Proteins; Cholesterol, LDL; Ezetimibe; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hypercholesterolemia; Indoles; Oligonucleotides; Oxazepines; Piperidines; Proprotein Convertase 9; Proprotein Convertases; Pyridines; Serine Endopeptidases; Serine Proteinase Inhibitors | 2009 |
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs.
Topics: Azetidines; Benzimidazoles; Benzodiazepines; Carrier Proteins; Cholesterol, LDL; Dicarboxylic Acids; Dyslipidemias; Ezetimibe; Fatty Acids; Humans; Hypolipidemic Agents; Lipoprotein(a); Oligonucleotides; Oxazolidinones; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases | 2013 |
Resistance and intolerance to statins.
Topics: Anticholesteremic Agents; Azetidines; Benzimidazoles; Bile Acids and Salts; Cholesterol, LDL; Drug Resistance; Drug Therapy, Combination; Drug Tolerance; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Multidrug Resistance-Associated Protein 2; Pharmacogenetics; Polymorphism, Genetic | 2014 |
Familial hypercholesterolemia treatments: Guidelines and new therapies.
Topics: Anticholesteremic Agents; Benzimidazoles; Biomarkers; Blood Component Removal; Cholesterol, LDL; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; PCSK9 Inhibitors; Phenotype; Practice Guidelines as Topic; Proprotein Convertase 9; Serine Proteinase Inhibitors; Treatment Outcome | 2018 |
Low-density lipoprotein cholesterol lowering treatment: the current approach.
Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Benzimidazoles; Bile Acids and Salts; Carrier Proteins; Cholesterol, LDL; Dicarboxylic Acids; Europe; Ezetimibe; Fatty Acids; Gene Expression; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Proprotein Convertase 9; RNA, Small Interfering | 2020 |
1 trial(s) available for ezetimibe and bms201038
| Article | Year |
|---|---|
Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Azetidines; Benzimidazoles; Carrier Proteins; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Microsomes; Middle Aged; Severity of Illness Index; Treatment Outcome | 2008 |
3 other study(ies) available for ezetimibe and bms201038
| Article | Year |
|---|---|
[Homozygous hypercholesterolemia - new therapeutic options in cases with complete lack of LDL- receptor].
Topics: Adult; Anticholesteremic Agents; Benzimidazoles; Blood Component Removal; Codon, Terminator; Combined Modality Therapy; Coronary Disease; DNA Mutational Analysis; Ezetimibe; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Myocardial Revascularization; Receptors, LDL; Simvastatin | 2016 |
Lipid-Lowering Agents and High HDL (High-Density Lipoprotein) Are Inversely Associated With Intracranial Aneurysm Rupture.
Topics: Adult; Aged; Aneurysm, Ruptured; Benzimidazoles; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Intracranial Aneurysm; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Oligonucleotides; PCSK9 Inhibitors; Propensity Score; Protective Factors | 2018 |
Lipid-Lowering Agents.
Topics: Antibodies, Monoclonal; Anticholesteremic Agents; Benzimidazoles; Caproates; Cholesterol, HDL; Cholesterol, LDL; Diacylglycerol O-Acyltransferase; Dicarboxylic Acids; Dyslipidemias; Ezetimibe; Fatty Acids; Genetic Therapy; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipoprotein(a); Oligonucleotides; RNA, Small Interfering | 2019 |